Abstract
Summary
PRRS, also known as Porcine Reproductive and Respiratory Syndrome, is a viral disease that occurs worldwide in all age groups. PRRD has two symptoms: reproductive failure or failure in breeding animals, and respiratory disease in pigs of any age.
The global market for PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Rising awareness about PRRS is driving the growth of the market. Another opportunity for the market includes increasing animal care spending and R&D activities in the veterinary biologics segment. Vaccinated pigs are expected to significantly reduce the frequency of wild-type virus transmission, helping to prevent dangerous diseases. Additionally, rising government investment is also expected to boost global demand for veterinary autologous vaccines during the forecast period. However, R&D costs may hinder the growth of the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by region & country, by Type, and by Application.
The PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine.
Market Segmentation
By Company
Merck
HIPRA
Sinopharm Animal Health Co., Ltd
Ceva Santé Animale
CAVAC
Bioveta
Jinyu Bio-Technology
Zoetis
Boehringer Ingelheim
Harbin Pharmaceutical Group
Segment by Type:
CH-1R Strain
PC Strain
Others
Segment by Application
Gilts
Sows
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Rising awareness about PRRS is driving the growth of the market. Another opportunity for the market includes increasing animal care spending and R&D activities in the veterinary biologics segment. Vaccinated pigs are expected to significantly reduce the frequency of wild-type virus transmission, helping to prevent dangerous diseases. Additionally, rising government investment is also expected to boost global demand for veterinary autologous vaccines during the forecast period. However, R&D costs may hinder the growth of the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by region & country, by Type, and by Application.
The PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine.
Market Segmentation
By Company
Merck
HIPRA
Sinopharm Animal Health Co., Ltd
Ceva Santé Animale
CAVAC
Bioveta
Jinyu Bio-Technology
Zoetis
Boehringer Ingelheim
Harbin Pharmaceutical Group
Segment by Type:
CH-1R Strain
PC Strain
Others
Segment by Application
Gilts
Sows
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Introduction
1.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size Forecast
1.2.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2019-2030)
1.2.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume (2019-2030)
1.2.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Price (2019-2030)
1.3 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Trends & Drivers
1.3.1 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Trends
1.3.2 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Drivers & Opportunity
1.3.3 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Challenges
1.3.4 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players Revenue Ranking (2023)
2.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2019-2024)
2.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players Sales Volume Ranking (2023)
2.4 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine
2.9 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Competitive Analysis
2.9.1 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CH-1R Strain
3.1.2 PC Strain
3.1.3 Others
3.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type
3.2.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type
3.3.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Gilts
4.1.2 Sows
4.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application
4.2.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application
4.3.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region
5.1.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region (2019-2024)
5.1.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region (2025-2030)
5.1.4 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Region
5.2.1 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
5.4.2 North America PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
5.5.2 Europe PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
5.7.2 South America PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value
6.2.1 Key Countries/Regions PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.3.2 United States PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.4.2 Europe PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.5.2 China PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.6.2 Japan PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.7.2 South Korea PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value, 2019-2030
6.9.2 India PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.1.5 Merck Recent Development
7.2 HIPRA
7.2.1 HIPRA Company Information
7.2.2 HIPRA Introduction and Business Overview
7.2.3 HIPRA PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 HIPRA PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.2.5 HIPRA Recent Development
7.3 Sinopharm Animal Health Co., Ltd
7.3.1 Sinopharm Animal Health Co., Ltd Company Information
7.3.2 Sinopharm Animal Health Co., Ltd Introduction and Business Overview
7.3.3 Sinopharm Animal Health Co., Ltd PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Sinopharm Animal Health Co., Ltd PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.3.5 Sinopharm Animal Health Co., Ltd Recent Development
7.4 Ceva Santé Animale
7.4.1 Ceva Santé Animale Company Information
7.4.2 Ceva Santé Animale Introduction and Business Overview
7.4.3 Ceva Santé Animale PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Ceva Santé Animale PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.4.5 Ceva Santé Animale Recent Development
7.5 CAVAC
7.5.1 CAVAC Company Information
7.5.2 CAVAC Introduction and Business Overview
7.5.3 CAVAC PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 CAVAC PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.5.5 CAVAC Recent Development
7.6 Bioveta
7.6.1 Bioveta Company Information
7.6.2 Bioveta Introduction and Business Overview
7.6.3 Bioveta PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Bioveta PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.6.5 Bioveta Recent Development
7.7 Jinyu Bio-Technology
7.7.1 Jinyu Bio-Technology Company Information
7.7.2 Jinyu Bio-Technology Introduction and Business Overview
7.7.3 Jinyu Bio-Technology PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Jinyu Bio-Technology PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.7.5 Jinyu Bio-Technology Recent Development
7.8 Zoetis
7.8.1 Zoetis Company Information
7.8.2 Zoetis Introduction and Business Overview
7.8.3 Zoetis PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Zoetis PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.8.5 Zoetis Recent Development
7.9 Boehringer Ingelheim
7.9.1 Boehringer Ingelheim Company Information
7.9.2 Boehringer Ingelheim Introduction and Business Overview
7.9.3 Boehringer Ingelheim PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Boehringer Ingelheim PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.9.5 Boehringer Ingelheim Recent Development
7.10 Harbin Pharmaceutical Group
7.10.1 Harbin Pharmaceutical Group Company Information
7.10.2 Harbin Pharmaceutical Group Introduction and Business Overview
7.10.3 Harbin Pharmaceutical Group PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Harbin Pharmaceutical Group PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Offerings
7.10.5 Harbin Pharmaceutical Group Recent Development
8 Industry Chain Analysis
8.1 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industrial Chain
8.2 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 PIG Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer